Abstract | INTRODUCTION: AREAS COVERED: The mechanism of action, adverse effect profile, and regulatory history of thalidomide and lenalidomide will be reviewed. The literature search for pain treatment includes case series and preliminary trials for CRPS, and case reports and case series for other chronic pain conditions. EXPERT OPINION:
Lenalidomide has a more favorable adverse effect profile compared to its parent compound thalidomide. Both agents, however, have significant potential adverse effects. Evidence of efficacy for chronic pain syndromes such as CRPS remains limited. Further studies are needed before these agents can be recommended for use in CRPS or other chronic pain syndromes.
|
Authors | Christopher Asher, Timothy Furnish |
Journal | Expert opinion on drug safety
(Expert Opin Drug Saf)
Vol. 12
Issue 3
Pg. 367-74
(May 2013)
ISSN: 1744-764X [Electronic] England |
PMID | 23442012
(Publication Type: Journal Article, Review)
|
Chemical References |
- Anti-Inflammatory Agents
- Immunologic Factors
- Thalidomide
- Lenalidomide
|
Topics |
- Anti-Inflammatory Agents
(adverse effects, therapeutic use)
- Chronic Pain
(drug therapy)
- Drug-Related Side Effects and Adverse Reactions
- Humans
- Immunologic Factors
(adverse effects, therapeutic use)
- Lenalidomide
- Thalidomide
(adverse effects, analogs & derivatives, therapeutic use)
|